Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.
severe tricuspid regurgitation (TR). For the hierarchical primary outcome, the win ratio favored TTVR using the Evoque device (Edwards Lifesciences; 2.02; 95% CI 1.56-2.62), with investigators ...
Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England ...
Among study participants with symptomatic, severe tricuspid regurgitation (TR), those randomized to TTVR, in lieu of medical therapy alone, had significantly better 1-year outcomes per win ratio ...
Rebecca T. Hahn, M.D., from the Columbia University Irving Medical Center in New York City, and colleagues randomly assigned 400 patients with severe symptomatic tricuspid regurgitation to undergo ...
Patients enrolled in the TRISCEND II trial had at least severe tricuspid regurgitation (TR). The EVOQUE valve was successfully implanted in 95.4 percent of patients, and of those who received the ...
multicenter study in the US to evaluate the safety and performance of the DUO™ System in patients with severe+ symptomatic tricuspid regurgitation, a severe heart condition that occurs when the ...
Patients enrolled in the TRISCEND II trial had at least severe tricuspid regurgitation (TR). The EVOQUE valve was successfully implanted in 95.4 percent of patients, and of those who received the ...